<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922894</url>
  </required_header>
  <id_info>
    <org_study_id>1607015110</org_study_id>
    <nct_id>NCT02922894</nct_id>
  </id_info>
  <brief_title>Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury</brief_title>
  <official_title>Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John D. Dingell VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>John D. Dingell VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate potential therapeutic approaches for sleep-disordered breathing&#xD;
      (SDB) in patients with chronic cervical spine injury (&gt;6 months post-injury).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cervical spinal cord injury demonstrate central sleep disordered breathing&#xD;
      manifesting as central sleep apnea or a periodic breathing pattern. Understanding the causes&#xD;
      of central sleep apnea may be critically important to understanding upper airway obstruction&#xD;
      in susceptible individuals, given the critical role of ventilatory motor output in&#xD;
      maintaining upper airway patency as evidenced by upper airway narrowing or occlusion at the&#xD;
      nadir of ventilator drive during periodic breathing. This study is likely to identify&#xD;
      therapeutic strategies that could be tested in large clinical trials, with the ultimate goal&#xD;
      of improving quality of life among patients with cervical SCI who also experience central&#xD;
      sleep disordered breathing.&#xD;
&#xD;
      To this end the research proposal is aimed as follows:&#xD;
&#xD;
      Specific Aim 1: Test the hypothesis that patients with cervical SCI will demonstrate greater&#xD;
      magnitude of long-term facilitation (LTF) following episodic hypoxia during sleep, compared&#xD;
      to patients with thoracic Spinal cord injury. This aim will be accomplished by measuring the&#xD;
      effect of acute episodic hypoxic ventilation and upper airway mechanics in both groups.&#xD;
&#xD;
      Specific Aim 2: Test the hypothesis that dampening peripheral chemoreceptor activity in&#xD;
      patients with cervical SCI and central sleep disordered breathing (SDB) with supplemental&#xD;
      oxygen will reduce central respiratory events and decrease respiratory variability during&#xD;
      sleep. The aim will be accomplished by providing supplemental oxygen to participants with&#xD;
      cervical SCI and central SDB.&#xD;
&#xD;
      Specific Aim 3: Test the hypothesis that administration of trazodone, in patients with&#xD;
      cervical spinal cord injury and central SDB will decrease respiratory related arousals and&#xD;
      central apnea index, and the propensity to develop central apnea, compared to placebo. To&#xD;
      accomplish this aim, the investigators will test the acute effect of trazodone on respiratory&#xD;
      related arousals and central sleep apnea, and the chronic effect on central apnea indices and&#xD;
      the CO2 reserve.&#xD;
&#xD;
      The investigators will study subjects with SCI at T6 or above who are not on artificial&#xD;
      ventilation. To characterize the sleep and breathing state of each subject, polysomnography&#xD;
      and upper airway collapsibility will be measured at baseline. Then the following experiments&#xD;
      will be conducted: an episodic hypoxia protocol vs normoxia will be used to determine whether&#xD;
      cervical SCI will demonstrate greater magnitude of LTF. Experiments will be conducted to see&#xD;
      whether dampening peripheral chemoreceptor activity in cervical SCI by giving supplemental&#xD;
      oxygen will reduce the central respiratory events and reduce the breathing variability during&#xD;
      sleep. A cross over experiment will be done to see whether administration of trazodone in&#xD;
      patients with cervical SCI and central SDB decreases respiratory-related arousals and central&#xD;
      apnea. The participant will be given the drug/placebo for one week then cross over after a 1&#xD;
      week wash out period to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tidal Volume</measure>
    <time_frame>1 Week</time_frame>
    <description>Change in tidal volume from baseline to recovery period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CO2 reserve (Delta-PETCO2-AT)</measure>
    <time_frame>1 Week</time_frame>
    <description>CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Apnea Hypopnea Index (AHI)</measure>
    <time_frame>1 week</time_frame>
    <description>AHI is used to indicate the severity of sleep apnea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hypocapnic apneic threshold</measure>
    <time_frame>1 week</time_frame>
    <description>The nadir pressure in the upper airway (supra-glotic pressure) prior to the occurrence of an arousal. This is a physiological parameter.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Acute episodic hypoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplemental oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>examine the effect of trazodone on breathing during sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acute episodic hypoxia</intervention_name>
    <description>The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.</description>
    <arm_group_label>Acute episodic hypoxia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Supplemental oxygen</intervention_name>
    <description>Supplemental oxygen therapy for 6 weeks</description>
    <arm_group_label>Supplemental oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>100mg before bedtime</description>
    <arm_group_label>Trazodone or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo pill before-bedtime</description>
    <arm_group_label>Trazodone or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Room air will be administered instead of episodic hypoxia or supplemental oxygen..</description>
    <arm_group_label>Acute episodic hypoxia</arm_group_label>
    <arm_group_label>Supplemental oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. healthy adults between the ages of 18 - 89&#xD;
&#xD;
          2. chronic spinal cord injury patients (T6 and above), &gt; 3 months since injury and not on&#xD;
             mechanical ventilation, and have not received mechanical ventilation via tracheostomy&#xD;
             in the past.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. subjects ≤ 17 yrs old&#xD;
&#xD;
          2. Pregnant and lactating females&#xD;
&#xD;
          3. History of head trauma that resulted in neurological symptoms or loss of consciousness&#xD;
&#xD;
          4. advanced heart, lung, metabolic, liver or chronic kidney disease.&#xD;
&#xD;
          5. severe obstructive or restrictive respiratory defect by PFTs or history of&#xD;
             tracheostomy&#xD;
&#xD;
          6. extreme obesity defined for this protocol as BMI ≥ 40 kg/m2 (to avoid the effect of&#xD;
             morbid obesity on ventilation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Safwan Badr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>John D. Dingell VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Safwan Badr, M.D.</last_name>
    <phone>313-576-3548</phone>
    <email>m.badr@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>John D. Dingell VA Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Safwan Badr, MD</last_name>
      <phone>313-576-3548</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

